Neoplasia/BPH

	Genetic insights revealed ADRB1 as potential target for clear cell renal cell carcinoma. Front Pharmacol Zhu H, Lin Q, Yu Z, Huang X. PMID: 42318352 [PubMed]
	Non-invasive evaluation of muscle invasion and survival prognosis in bladder cancer using enhanced CT-based deep learning radiomics: a multi-center real-world cohort study. Mil Med Res He YB, Hu J, Liu Z, Xiao ZC, Liu JH, Liang HS, Deng WZ, Li ZW, Zhang J, Long JQ, Gao N, Huang B, Guo X, Ou ZY, Chen JB, Liu PH, Chen MF, Li HH, Wang RZ, Guan X, Tong SY, Li YL, He W, Zhao YH, Cai ZY, Gan Y, Zhao C, Cui Y, Dai YQ, Cai Y, Nie ZY, Zhou WM, Zhou BH, Hu MH, Fan BY, Deng DS, Zu XB. PMID: 42318044 [PubMed - indexed for MEDLINE]
	A diagnostic signature derived from NK cell related genes in prostate cancer: insights from integrated scRNA-seq and bulk RNA-seq analyses with functional validation of KIT. Front Immunol Chen Z, Zhou F, Tian J, Lv Q, Wang D, Fan S. PMID: 42317356 [PubMed - indexed for MEDLINE]
	Structured micro-ultrasonography training improves prostate cancer detection and management decisions. BJU Int Wessendorf MP, Mangold MH, Baumann G, Winter N, Braun JJ, Lehmberg J, Studier-Fischer A, Brochhausen C, Michel MS, Carlsson SV, Kowalewski KF, Haney-Aubert CM. PMID: 42316473 [PubMed - as supplied by publisher]
	The glycobiology of prostate cancer: an update. Oncogene Hodgson K, Orozco-Moreno M, Peng Z, Blencoe L, Sharp MJ, Smith E, Grimsley G, Elliott DJ, Beatson R, Drake RR, Munkley J. PMID: 42315913 [PubMed - as supplied by publisher]
	LINC00222 regulates FOXO3 to interfere with β-catenin signaling pathway and suppresses prostate cancer progression. Sci Rep Li H, Zhao W, Deng Y, Liu Z, Li J, Tian S. PMID: 42315881 [PubMed - as supplied by publisher]
	Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study. Eur J Nucl Med Mol Imaging Leslie C, Al-Ogaili Z, Oh L, Slattery T, Shaji S, Marsavela G, Mills A, Stone C, Ferguson T. PMID: 42315637 [PubMed - as supplied by publisher]
	The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol. BMJ Open van der Gaag S, Vis A, Bartelink I, Hendrikse H, Oprea-Lager DE. PMID: 42315278 [PubMed - indexed for MEDLINE]
	Retzius-Sparing Laparoscopic Radical Prostatectomy in A Nonrobotic Setting: A 30-Case Implementation Series With Minimum 18-Month Follow-Up. Asian J Endosc Surg Fernandez-Alberti J, Ernst G, Scolari G, Lopez AV, Panzardi N, Featherston M, Martinez PM. PMID: 42315251 [PubMed - indexed for MEDLINE]
	A Report of Thirteen Non-Conventional FLCN-Mutated (Renal) Tumors (FMT) and a Discussion of Proposed Diagnostic Criteria, Convergent FLCN/TFEB and FLCN/MITF E318K Signaling, and FLCN immunohistochemistry. Hum Pathol Gupta S, Sterner RM, Hasumi H, Jikuya R, Nakagawa H, Kryvenko ON, Jorda M, Torell NR, Stander Z, Colef RG, Tekin B, Whaley RD, Hernandez LH, Jimenez RE, Lucas PC, Kipp BR, Shen W, Erickson LA, Dasari S, Cheville JC. PMID: 42315013 [PubMed - as supplied by publisher]
	Elevated allostatic load, adverse body composition, and reduced overall survival in a retrospective cohort of men with newly diagnosed metastatic prostate cancer. J Acad Nutr Diet Sheean PM, O'Connor P, Bolouri M, Wozniak A, Joyce C, Vasilopoulos V, Badami A. PMID: 42314899 [PubMed - as supplied by publisher]
	Antidiabetic medications and the risk of bladder cancer in patients with diabetes mellitus: A systematic review and meta-analysis. Urol Oncol Lei D, Wu JH, Zeng XH, Xu R, Zheng SS, Zhu XJ, Yang JA. PMID: 42314323 [PubMed - as supplied by publisher]
	Mechanisms of resistance to androgen deprivation therapy in prostate cancer. Mol Aspects Med Bensalim I, Belyamani L, Boutayeb S, Bourais I. PMID: 42314224 [PubMed - as supplied by publisher]
	Hematological Inflammation Markers in the Prediction of Clinically Significant Prostate Cancer and the Individualization of Biopsy Decisions for PI-RADS 3 Lesions: A Two-Center Retrospective Study. Prostate Eroglu A, Gezmis CT, Arikan Y, Cilesiz NC, Koras O, Emir B, Balci MBC, Keskin MZ. PMID: 42314010 [PubMed - as supplied by publisher]
	Metabolic Reprogramming in Renal Cell Carcinoma: A Scoping Review with Quantitative Integration of Metabolomic Studies. J Proteome Res Amaro F, Carvalho M, Bastos ML, Guedes de Pinho P, Pinto J. PMID: 42313837 [PubMed - as supplied by publisher]
	Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Nonrandomized Clinical Trial. JAMA Oncol Zilli T, Franzese C, Guckenberger M, Giaj-Levra N, Mach N, Achard V, Vial N, McDonald A, Alongi F, Scorsetti M, Constantin G, Bertaut A, Miralbell R. PMID: 42313395 [PubMed - as supplied by publisher]
	Downregulation of long non-coding RNAs PCAT18, HOTAIR, and CTBP1-AS in prostate malignancies. Mol Biol Rep Pouresmaeili F, Mohammadi M, Hosseini J, Aarabi A, Fazeli Z, Tabatabaie SFS. PMID: 42313281 [PubMed - indexed for MEDLINE]
	Association between the G-protein-coupled estrogen receptor 1 and prostate cancer in the Slovak population. Mol Biol Rep Me, Kliment J, Du, Evin D, Kno, Kme, Dobrota D, Jure. PMID: 42313278 [PubMed - indexed for MEDLINE]
	Preoperative MRI Model for Predicting Inferior Vena Cava Wall Invasion in Renal Cell Carcinoma with Tumor Thrombus. Radiol Imaging Cancer Wen XW, Zhou SP, Kang HH, Zhao J, Bai X, Wang MF, Chen YB, Yi SC, Li CB, Ding XH, Huang QB, Wang HY. PMID: 42313081 [PubMed - indexed for MEDLINE]
	Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-Analysis. Radiol Imaging Cancer Ulaner GA, Parihar AS, Calais J, Sutcliffe S, Schoones JW. PMID: 42313080 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 188747

Page 1 of 9438



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy